<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045121</url>
  </required_header>
  <id_info>
    <org_study_id>HSRG/0042/2013</org_study_id>
    <nct_id>NCT02045121</nct_id>
  </id_info>
  <brief_title>Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management</brief_title>
  <official_title>A Multicentre Randomised Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis in Patients With a Malignant Pleural Effusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <brief_summary>
    <textblock>
      Malignant pleural effusion (MPE) accounts for 50% of all pleural effusions and affects about
      300,000 patients annually (UK and USA). Lung and breast cancers account for majority of
      malignant pleural effusions; 1 in 3 breast cancer, 1 in 4 lung cancer as well as &gt; 90% of
      patients with mesothelioma develop pleural effusions. Breathlessness from MPE is disabling
      and impairs quality of life. Median survival ranges between 4-6 months. Although
      thoracentesis provides effective symptom relief, most effusions recur and pleurodesis is the
      standard of care. Pleurodesis can be performed via chest tube or applied during pleuroscopy,
      and talc is the most effective agent. For successful pleurodesis to occur the underlying lung
      must expand after fluid drainage and trapped lung due to metastatic disease occurs up to 30%.
      Symptomatic patients require hospitalization for these procedures which are likely to fail if
      trapped lungs are encountered, and pose significant burden to health services. Tunneled
      indwelling pleural catheter (IPC) is emerging as a viable alternative which provides access
      to the pleural space for fluid drainage when breathlessness arise. IPC can be performed at
      ambulatory setting without hospital admission. Case series have demonstrated long-term safety
      of IPC even in patients undergoing chemotherapy with acceptable complication rates. By
      keeping the pleural cavity free of fluid, IPC has led to spontaneous pleurodesis in 50% of
      patients, which allows its removal. Presently IPC is indicated for trapped lung or when talc
      pleurodesis has failed. A randomised comparative trial with talc pleurodesis is necessary to
      determine role of IPC as first-line therapy of MPE, if IPC leads to reduction in
      hospitalizations, adverse events and healthcare costs, and if it improves quality of life.
      The multicenter trial randomizes symptomatic patients 1:1 to IPC or talc pleurodesis, and
      endpoints include hospitalization days till death or end of study, adverse events, quality of
      life, and healthcare costs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of hospital days for all causes following intervention</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hospital days computed for pleural effusion related cause</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathlessness score</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported quality of life scores</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health costs computation</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pleural Effusion, Malignant</condition>
  <arm_group>
    <arm_group_label>Indwelling Pleural Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Talc Pleurodesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if &gt;75% of visceral and parietal pleura in direct contact on chest x-ray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Indwelling Pleural Catheter</intervention_name>
    <arm_group_label>Indwelling Pleural Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Talc Pleurodesis</intervention_name>
    <arm_group_label>Talc Pleurodesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic malignant pleural effusion requiring intervention

        Exclusion Criteria:

          -  &lt;18 years of age

          -  pregnant or lactating patients

          -  expected survival &lt;3 months

          -  chylothorax

          -  previous attempted pleurodesis

          -  pleural infection

          -  leukocytopaenia (&lt;1.0 x 10^9/L)

          -  uncorrectable bleeding diathesis

          -  inability to give informed consent or comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pyng Lee, MBBS, MRCP, MMED, FAMS, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pyng Lee, MBBS, MRCP, MMED, FAMS, FCCP</last_name>
    <email>mdclp@nus.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Respiratory and Critical Care Medicine, National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pyng Lee</last_name>
      <phone>65-67726533</phone>
      <email>mdclp@nus.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Pyng Lee, MBBS, MRCP, MMED, FAMS, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Davies HE, Lee YCG. Pleurodesis. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases. 2nd ed. London, U.K.: Arnold Press; 2008:569-82.</citation>
  </reference>
  <reference>
    <citation>Mishra E, Davies HE, Lee YCG. Malignant pleural disease in primary lung cancer. In: Spiro SG, Janes SM, Huber RM, eds. Thoracic Malignancies. 3rd ed ed. Sheffield, U.K.: European Respiratory Society Journals Ltd; 2009:318-35.</citation>
  </reference>
  <reference>
    <citation>Lee YC, Wilkosz S. Malignant pleural effusions: fixing the leaky faucet. Am J Respir Crit Care Med. 2008 Jul 1;178(1):3-5. doi: 10.1164/rccm.200804-616ED.</citation>
    <PMID>18565960</PMID>
  </reference>
  <reference>
    <citation>West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med. 2006 Jun;27(2):335-54. Review.</citation>
    <PMID>16716822</PMID>
  </reference>
  <reference>
    <citation>Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest. 2000 Jan;117(1):73-8.</citation>
    <PMID>10631202</PMID>
  </reference>
  <reference>
    <citation>Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest. 2000 Jan;117(1):79-86.</citation>
    <PMID>10631203</PMID>
  </reference>
  <reference>
    <citation>Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005 Jul 30-Aug 5;366(9483):397-408. Review.</citation>
    <PMID>16054941</PMID>
  </reference>
  <reference>
    <citation>Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ; Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005 Mar;127(3):909-15.</citation>
    <PMID>15764775</PMID>
  </reference>
  <reference>
    <citation>Davies HE, Lee YC, Davies RJ. Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax. 2008 Jul;63(7):572-4. doi: 10.1136/thx.2007.092940.</citation>
    <PMID>18587029</PMID>
  </reference>
  <reference>
    <citation>Lee YC, Fysh ET. Indwelling pleural catheter: changing the paradigm of malignant effusion management. J Thorac Oncol. 2011 Apr;6(4):655-7. doi: 10.1097/JTO.0b013e3182114aa0.</citation>
    <PMID>21623256</PMID>
  </reference>
  <reference>
    <citation>van den Toorn LM, Schaap E, Surmont VF, Pouw EM, van der Rijt KC, van Klaveren RJ. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer. 2005 Oct;50(1):123-7.</citation>
    <PMID>15998551</PMID>
  </reference>
  <reference>
    <citation>Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J. 2007 Oct;30(4):759-62. Epub 2007 Jun 13.</citation>
    <PMID>17567670</PMID>
  </reference>
  <reference>
    <citation>Putnam JB Jr, Walsh GL, Swisher SG, Roth JA, Suell DM, Vaporciyan AA, Smythe WR, Merriman KW, DeFord LL. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg. 2000 Feb;69(2):369-75.</citation>
    <PMID>10735665</PMID>
  </reference>
  <reference>
    <citation>Putnam JB Jr, Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS, Lee RB, Payne DK, Graeber G, Kovitz KL. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999 Nov 15;86(10):1992-9.</citation>
    <PMID>10570423</PMID>
  </reference>
  <reference>
    <citation>Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, Kachala SS, Zlobinsky M, Rusch VW, Adusumilli PS. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. J Thorac Oncol. 2011 Apr;6(4):762-7. doi: 10.1097/JTO.0b013e31820d614f.</citation>
    <PMID>21325982</PMID>
  </reference>
  <reference>
    <citation>Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011 Jan;26(1):70-6. doi: 10.1007/s11606-010-1472-0. Epub 2010 Aug 10. Review.</citation>
    <PMID>20697963</PMID>
  </reference>
  <reference>
    <citation>Morel A, Mishra E, Medley L, Rahman NM, Wrightson J, Talbot D, Davies RJ. Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion. Thorax. 2011 May;66(5):448-9. doi: 10.1136/thx.2009.133504. Epub 2010 Sep 29.</citation>
    <PMID>20880866</PMID>
  </reference>
  <reference>
    <citation>Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest. 2007 Apr;131(4):1232-4.</citation>
    <PMID>17426232</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University Hospital, Singapore</investigator_affiliation>
    <investigator_full_name>Medicine</investigator_full_name>
    <investigator_title>A/Prof Lee Pyng</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

